Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Perez, Angela, Montalban-Bravo, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515843/
https://www.ncbi.nlm.nih.gov/pubmed/31156799
http://dx.doi.org/10.1177/2040620719847059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515843/
https://www.ncbi.nlm.nih.gov/pubmed/31156799
http://dx.doi.org/10.1177/2040620719847059

Ejemplares similares